Compare · NBP vs NVO
NBP vs NVO
Side-by-side comparison of NovaBridge Biosciences (NBP) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NBP and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 1166.8x NBP ($148.8M).
- Over the past year, NBP is down 75.6% and NVO is down 30.4% - NVO leads by 45.2 points.
- NBP has been more active in the news (4 items in the past 4 weeks vs 3 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 1 for NBP).
- Company
- NovaBridge Biosciences
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $148.8M
- $173.66B
- 1M return
- -22.32%
- -10.14%
- 1Y return
- -75.58%
- -30.36%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 4
- 3
- Recent ratings
- 1
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NBP
- SEC Form 6-K filed by NovaBridge Biosciences
- Hiteck Licenses Investigational Next-Generation NGF Eye Drop HT006.2.2 to Visara for Neurotrophic Keratitis Outside Greater China
- Visara Expands Ophthalmology Pipeline with Exclusive License for Investigational Nerve Growth Factor Therapy for Neurotrophic Keratitis
- NovaBridge Biosciences Announces Expanded Givastomig Safety and Efficacy Data to be Presented at the European Society for Medical Oncology 2026
- Chief Medical Officer Dennis Phillip Andrew converted options into 23,695 units of Ordinary Shares and sold $5,828 worth of Ordinary Shares (8,209 units at $0.71), increasing direct ownership by 10% to 173,427 units (SEC Form 4)
- Chief Bus. Development Officer Cao Sean Wuxiong sold $79,904 worth of Ordinary Shares (107,978 units at $0.74), decreasing direct ownership by 29% to 266,467 units (SEC Form 4) (for tax liability)
- SEC Form 3 filed by new insider Dewhurst Martin William
- Chief Bus. Development Officer Cao Sean Wuxiong converted options into 339,372 units of Ordinary Shares, increasing direct ownership by 968% to 374,445 units (SEC Form 4)
- SEC Form 6-K filed by NovaBridge Biosciences
- SEC Form 6-K filed by NovaBridge Biosciences
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank